Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.

LaForce FM, Okwo-Bele JM.

Health Aff (Millwood). 2011 Jun;30(6):1049-57. doi: 10.1377/hlthaff.2011.0328.

2.

Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa.

Bishai DM, Champion C, Steele ME, Thompson L.

Health Aff (Millwood). 2011 Jun;30(6):1058-64. doi: 10.1377/hlthaff.2011.0295.

3.

Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa.

Miller MA, Wenger J, Rosenstein N, Perkins B.

Pediatr Infect Dis J. 1999 Dec;18(12):1051-9.

PMID:
10608623
4.

Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Dec 21;61(50):1025-8.

5.

Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.

Okoko BJ, Idoko OT, Adegbola RA.

Vaccine. 2009 Mar 23;27(14):2023-9. doi: 10.1016/j.vaccine.2008.11.092. Epub 2008 Dec 16. Review.

PMID:
19095025
6.

Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso.

Vogel G.

Science. 2003 Mar 7;299(5612):1499-501. No abstract available.

PMID:
12624241
7.

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM.

Vaccine. 2012 May 30;30 Suppl 2:B40-5. doi: 10.1016/j.vaccine.2011.12.073. Review.

PMID:
22607898
8.

From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.

Aguado MT, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin GW.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S391-5. doi: 10.1093/cid/civ593. Review.

9.

Neisseria meningitidis serogroup A vaccines: an overview.

Vergnano S, Heath P.

Expert Rev Vaccines. 2003 Aug;2(4):571-82. Review.

PMID:
14711341
10.

[Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].

da Silva A, Parent du Châtelet I, Beckr Gaye A, Dompnier JP, Seck I.

Sante. 2003 Oct-Dec;13(4):215-23. French.

PMID:
15047438
11.

Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.

Meyer SA, Kambou JL, Cohn A, Goodson JL, Flannery B, Medah I, Messonnier N, Novak R, Diomande F, Djingarey MH, Clark TA, Yameogo I, Fall A, Wannemuehler K.

Vaccine. 2015 Mar 17;33(12):1492-8. doi: 10.1016/j.vaccine.2015.01.043. Epub 2015 Jan 28.

PMID:
25636915
12.

[Clonal expansion of Neisseria meningitidis W135. Epidemiological implications for the African meningitis belt].

du Châtelet IP, Alonso JM, Taha MK.

Bull Soc Pathol Exot. 2002 Dec;95(5):323-4; discussion 324-5. Review. French.

PMID:
12696368
13.

Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Dec 21;61(50):1022-4.

14.

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.

Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S.

Vaccine. 2009 Jun 24;27 Suppl 2:B13-9. doi: 10.1016/j.vaccine.2009.04.062. Epub 2009 May 27. Review.

PMID:
19477559
15.

Meningococcal vaccine in travelers.

Wilder-Smith A.

Curr Opin Infect Dis. 2007 Oct;20(5):454-60. Review.

PMID:
17762777
16.

Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.

Dakar discussion group on priorities for research on epidemic meningococcal disease in Africa, Altmann D, Aseffa A, Bash M, Basta N, Borrow R, Broome C, Caugant D, Clark T, Collard JM, Djingarey M, Goldblatt D, Greenwood B, Griffiths U, Hajjeh R, Hassan-King M, Hugonnet S, Kimball AM, LaForce M, MacLennan C, Maiden MC, Manigart O, Mayer L, Messonnier N, Moisi J, Moore K, Moto DD, Mueller J, Nascimento M, Obaro S, Ouedraogo R, Page AL, Perea W, Pluschke G, Preziosi MP, Sow S, Stephens D, Stuart J, Thomson M, Tiendrebeogo S, Trape JF, Vernet G.

Vaccine. 2013 Mar 1;31(11):1453-7. doi: 10.1016/j.vaccine.2012.12.035. Epub 2012 Dec 27.

17.

Risk of epidemic meningitis in Africa: a cause for concern.

[No authors listed]

Wkly Epidemiol Rec. 2007 Mar 9;82(10):79-87. English, French. No abstract available.

18.

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.

Mueller JE, Borrow R, Gessner BD.

Expert Rev Vaccines. 2006 Jun;5(3):319-36. Review.

PMID:
16827617
19.

Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks?

Roberts L.

Science. 2010 Dec 10;330(6010):1466-7. doi: 10.1126/science.330.6010.1466. No abstract available.

PMID:
21148362
20.

Meningitis epidemics in Africa: a brief overview.

Teyssou R, Muros-Le Rouzic E.

Vaccine. 2007 Sep 3;25 Suppl 1:A3-7. Epub 2007 May 15. Review.

PMID:
17643560
Items per page

Supplemental Content

Write to the Help Desk